Literature DB >> 8935602

Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome.

A Sartorio1, A Conti, S Ferrario, E Passini, T Re, B Ambrosi.   

Abstract

Serum bone Gla protein, a marker of bone formation, and carboxyterminal cross-linked telopeptide of type I collagen levels, an index of bone resorption, were evaluated in eight patients with active Cushing's syndrome and in four with 'preclinical' Cushing's syndrome, before and after surgery. In basal conditions, serum bone Gla protein levels were significantly lower (p < 0.0001) in patients with active Cushing's syndrome (1.0 +/- 0.35 ng/ml) than in controls (5.4 +/- 0.15 ng/ml); two out of four patients with the 'preclinical' form had reduced bone Gla protein levels, while in the other two cases levels were in the normal range. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (3.0 +/- 0.4 ng/ml), although slightly reduced, were similar to those recorded in controls (4.1 +/- 0.3 ng ml), both in patients with active and with preclinical Cushing's syndrome. After surgery serum levels of both marker proteins significantly increased in seven out of eight patients with active Cushing's syndrome; in one patient, who was not cured after surgery, bone Gla proteins levels remained lower than in normals, while levels of carboxyterminal cross-linked telopeptide of type I collagen had a transient increase after six months. In the two patients with a 'preclinical' Cushing's syndrome who underwent surgery, a significant rise of the levels of both marker proteins was observed, similar to that observed in patients with active Cushing's syndrome. It was concluded that serial determinations of these new markers of bone formation and resorption may be usefully employed to follow-up the clinical course of Cushing's syndrome and provide information on the rate of bone turnover in response to medical and/or surgical therapies. Moreover, the evaluation of these markers in preclinical states of Cushing's syndrome might suggest the need for surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935602      PMCID: PMC2398525          DOI: 10.1136/pgmj.72.849.419

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  26 in total

1.  Roentgenologic changes of the skeletal system in Cushing's syndrome.

Authors:  W J HOWLAND; D G PUGH; R G SPRAGUE
Journal:  Radiology       Date:  1958-07       Impact factor: 11.105

2.  Mechanisms of glucocorticoid-induced osteopenia: role of parathyroid glands.

Authors:  S C Kukreja; E N Bowser; G K Hargis; W J Henderson; G A Williams
Journal:  Proc Soc Exp Biol Med       Date:  1976-07

Review 3.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

Review 4.  Corticosteroids and bone: a review.

Authors:  P Burckhardt
Journal:  Horm Res       Date:  1984

5.  Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome.

Authors:  P J Meunier; D W Dempster; C Edouard; M C Chapuy; M Arlot; S Charhon
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

6.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

7.  Modifications in bone-GLA protein (BGP) and aminoterminal propeptide of type III procollagen (PIIINP) levels in one patient with Cushing's syndrome.

Authors:  A Sartorio; B Ambrosi; A Conti; M Monzani; G Faglia
Journal:  Horm Metab Res       Date:  1991-05       Impact factor: 2.936

8.  Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy.

Authors:  O S Gluck; W A Murphy; T J Hahn; B Hahn
Journal:  Arthritis Rheum       Date:  1981-07

9.  Calcium and phosphorus homeostasis in man. Effect of corticosteroids.

Authors:  B P Lukert; J S Adams
Journal:  Arch Intern Med       Date:  1976-11

10.  Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.

Authors:  A Piovesan; M Terzolo; G Reimondo; A Pia; A Codegone; G Osella; A Boccuzzi; P Paccotti; A Angeli
Journal:  Horm Metab Res       Date:  1994-05       Impact factor: 2.936

View more
  5 in total

Review 1.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

2.  Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.

Authors:  A Conti; A Sartorio; S Ferrero; S Ferrario; B Ambrosi
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

3.  Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.

Authors:  J Majnik; N Szücs; A Patócs; M Tóth; K Balogh; I Varga; E Gláz; K Rácz
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

4.  Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Alexander G Solodovnikov; Liudmila Y Rozhinskaya; Larisa K Dzeranova; Ivan I Dedov
Journal:  Bonekey Rep       Date:  2016-06-15

Review 5.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.